We report a rare subtype of quadricuspid aortic valve (QAV) associated with moderate aortic regurgitation in a 17-year old woman symptomatic for palpitations. The patient was admitted to our department for cardiac evaluation due to a previous diagnosis of bicuspid aortic valve; she underwent a new two-dimensional echocardiography revealing a rare type of quadricuspid aortic valve with a moderate regurgitation. For further investigating potentially associated abnormalities, patient was referred to Cardiac MRI; MRI showed no other abnormalities and confirmed echocardiographic findings. Quadricuspid aortic valve is a rare form of congenital valvular anomaly often occasionally diagnosed. In most cases this malformation causes a valve dysfunction, commonly aortic regurgitation, and can be associated with other cardiac abnormalities such as ventricular or atrial septal defect, anomalies of coronary arteries, patent ductus arteriosus, subaortic fibromuscolar stenosis and mitral valve malformation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4081/monaldi.2011.186 | DOI Listing |
The zebrafish is a valuable model organism for studying cardiac development and diseases due to its many shared aspects of genetics and anatomy with humans and ease of experimental manipulations. Computational fluid-structure interaction (FSI) simulations are an efficient and highly controllable means to study the function of cardiac valves in development and diseases. Due to their small scales, little is known about the mechanical properties of zebrafish cardiac valves, limiting existing computational studies of zebrafish valves and their interaction with blood.
View Article and Find Full Text PDFAnatol J Cardiol
January 2025
Department of Cardiothoracic Surgery Research, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA ; Department of Cardiothoracic Surgery, Lankenau Heart Institute, Main Line Health Wynnewood, Pennsylvania, USA.
Background: To evaluate the clinical outcomes of valve-in-valve transcatheter aortic valve replacement (ViV TAVR) with newer-generation self-expanding Evolut valves according to the size of the failed surgical bioprosthesis.
Methods: This single-center retrospective study evaluated consecutive patients undergoing ViV TAVR with the Evolut Pro/Pro+/Fx between 2018 and 2022. These patients were compared based on the true internal diameter (ID) of the failed bioprosthesis, specifically ≤19 mm (small group) vs.
Ann Noninvasive Electrocardiol
January 2025
Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Background: Electrocardiograms (EKGs) are routinely performed in pregnant patients with pre-existing cardiovascular disease. However, in pregnant patients with congenital heart disease (CHD), EKG changes during gestation have not been explored.
Methods: We performed a retrospective study of pregnant patients with CHD enrolled in the STORCC initiative.
Gen Thorac Cardiovasc Surg Cases
January 2025
Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, 811-1 Kimiidera, Wakayama City, Wakayama, 641-8509, Japan.
Patients with coronary artery disease undergoing trans-catheter aortic valve implantation (TAVI) often receive TAVI alone. However, in cases of severe coronary lesions or anticipated difficulty in coronary access post-TAVI, percutaneous coronary intervention or coronary artery bypass grafting may be necessary. We performed simultaneous gastroepiploic artery to posterior descending artery bypass and TAVI in two patients with severe calcification of the right coronary artery ostium which is unsuitable for percutaneous intervention.
View Article and Find Full Text PDFCardiovasc Interv Ther
January 2025
Division of Cardiology, Department of Medicine, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama, Osaka, 589-8511, Japan.
Transcatheter aortic valve implantation (TAVI) using the NAVITOR system has been relatively underreported due to its recent introduction in Japan. This study aimed to assess the short-term outcomes of TAVI with the NAVITOR in real-world clinical practice. Patients with severe aortic stenosis who underwent TAVI using the NAVITOR system at our institution between December 2022 and December 2023 were prospectively enrolled.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!